Skinject: Drug delivery patch for skin cancer

Louis Falo Jr., MD, PhD. Bioengineering PI
Chairman, Department of Dermatology
Professor, Departments of Dermatology and Bioengineering
Pittsburgh Clinical and Translational Science Institute,
The McGowan Institute for Regenerative Medicine,
The University of Pittsburgh Cancer Institute

Lisa Grandinetti, MD Associate Professor, Department of Dermatology
University of Pittsburgh School of Medicine
Director, Residency Programs

Skin cancer is the most commonly occurring cancer in the United States. After the age of 65, 50%of the population will develop skin cancer with the majority diagnosed with Basal Cell Carcinoma (BCC). BCC occurs typically on the face, head or neck and is a highly disfiguring disease. Current therapies involve invasive surgical procedures that are time-consuming, associated with patient recovery/morbidity and are expensive. PatchIT TM  is novel, single use, topical drug delivery patch that, like a 'Band-Aid', is applied to the affected skin of those diagnosed with skin cancer. It is based on a proprietary Micro-Needle Array drug delivery platform that uniquely delivers a potent generic chemotherapeutic agent and modifier to kill existing skin cancer and induce a memory immune response to prevent cancer re-occurrence. This project has confirmed high physician and patient acceptance from initial customer feedback and has already received immense interest from investors at all showcased platforms.